Human PD-L1 inhibitor V - 1 mg
- Cat.Number : AS-65585
- Manufacturer Ref. :
-
Availability :
In stock
Alternative choices
Programed cell death 1 (PD-1) receptor and its ligand PD-L1 are crucial immune checkpoints to downregulate T cell activation, tolerance and immunopathology. Several types of cancer cells were identified to overexpress PD-L1 so as to escape from the PD-1/PD-L1 immunosurveillance mechanism. This peptide, hPDL-1 inhibitor V binds to human PD-1 and inhibits PD-1/PD-L1 binding. It has anchor residues (underlined), LDYVNRRKMYQ that show a great impact on the binding of hPD-L1 to hPD-1. Developing inhibitors specifically blocking the PD-1/PD-L1 pathway became popular approach to cancer treatment.
Specifications
| Chemistry | |
| Sequence one letter code |
|
|---|---|
| Sequence three letter code |
|
| Molecular Formula |
|
| Molecular Mass/ Weight |
|
| Modification | |
| Conjugation |
|
| Quantity & Purity | |
| Purity |
|
| Storage & stability | |
| Form |
|
| Storage Conditions |
|
| Activity | |
| Biomarker Target | |
| Research Area | |
| Sub-category Research Area | |
| Usage |
|
| Source | |
| Source / Species |
|
Downloads
You may also be interested in the following product(s)
SensoLyte® Rh110 Matriptase Activity Assay Kit Fluorimetric - 1 kit
References
A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet.
Clin Transl Med . 2017 Dec 01 ; 6(1) 3 | DOI : 10.1186/s40169-016-0130-5
- G. D'Errico
- et al
Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor
Oncotarget . 2016 Oct 04 ; 7(40) 64967 | DOI : 10.18632/oncotarget.11274
- Q. Li
- et al
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
Front Immunol . 2016 Dec 12 ; 7 550 | DOI : 10.3389/fimmu.2016.00550
- K. Bardhan
- et al